Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Major Shareholder Sells $152,994.96 in Stock

Share on StockTwits

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) major shareholder Matt Davidson sold 13,212 shares of the firm’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $11.58, for a total value of $152,994.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Matt Davidson also recently made the following trade(s):

  • On Monday, July 8th, Matt Davidson sold 12,529 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.27, for a total value of $141,201.83.
  • On Tuesday, July 2nd, Matt Davidson sold 33,521 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.63, for a total value of $389,849.23.
  • On Tuesday, June 25th, Matt Davidson sold 210 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.04, for a total value of $2,108.40.
  • On Thursday, June 13th, Matt Davidson sold 2,131 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $9.65, for a total value of $20,564.15.
  • On Tuesday, June 11th, Matt Davidson sold 4,345 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.49, for a total value of $36,889.05.
  • On Thursday, June 6th, Matt Davidson sold 5,507 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $7.27, for a total value of $40,035.89.
  • On Monday, June 3rd, Matt Davidson sold 4,110 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $7.36, for a total value of $30,249.60.
  • On Wednesday, May 29th, Matt Davidson sold 2,100 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.41, for a total value of $17,661.00.
  • On Thursday, May 23rd, Matt Davidson sold 2,422 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.80, for a total value of $21,313.60.
  • On Monday, May 20th, Matt Davidson sold 1,800 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.95, for a total value of $16,110.00.

Shares of VRCA stock opened at $11.00 on Friday. The firm’s 50 day moving average is $9.52. The stock has a market capitalization of $289.48 million and a PE ratio of -7.80. Verrica Pharmaceuticals Inc has a twelve month low of $6.44 and a twelve month high of $19.10.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.02). Equities analysts predict that Verrica Pharmaceuticals Inc will post -1.36 EPS for the current fiscal year.

Several research analysts have recently issued reports on the company. Zacks Investment Research cut Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. HC Wainwright lifted their price target on Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, June 27th.

Hedge funds have recently made changes to their positions in the stock. New York State Common Retirement Fund purchased a new position in Verrica Pharmaceuticals during the fourth quarter valued at approximately $28,000. Rhumbline Advisers purchased a new position in Verrica Pharmaceuticals during the first quarter valued at approximately $111,000. Bank of New York Mellon Corp raised its position in Verrica Pharmaceuticals by 39.1% during the fourth quarter. Bank of New York Mellon Corp now owns 16,662 shares of the company’s stock valued at $136,000 after acquiring an additional 4,681 shares in the last quarter. Geode Capital Management LLC raised its position in Verrica Pharmaceuticals by 31.7% during the fourth quarter. Geode Capital Management LLC now owns 36,906 shares of the company’s stock valued at $300,000 after acquiring an additional 8,885 shares in the last quarter. Finally, Pura Vida Investments LLC raised its position in Verrica Pharmaceuticals by 219.6% during the fourth quarter. Pura Vida Investments LLC now owns 63,916 shares of the company’s stock valued at $521,000 after acquiring an additional 43,916 shares in the last quarter. Institutional investors own 34.31% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Recommended Story: What is dollar cost averaging (DCA)?

Insider Buying and Selling by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Slack  Earns Neutral Rating from Analysts at Credit Suisse Group
Slack Earns Neutral Rating from Analysts at Credit Suisse Group
Slack  Coverage Initiated by Analysts at Morgan Stanley
Slack Coverage Initiated by Analysts at Morgan Stanley
Solaris Oilfield Infrastructure  Coverage Initiated by Analysts at Citigroup
Solaris Oilfield Infrastructure Coverage Initiated by Analysts at Citigroup
Tanger Factory Outlet Centers  Upgraded to “Hold” at Zacks Investment Research
Tanger Factory Outlet Centers Upgraded to “Hold” at Zacks Investment Research
Sterling Bancorp  Coverage Initiated at B. Riley
Sterling Bancorp Coverage Initiated at B. Riley
Restoration Hardware  Upgraded by ValuEngine to “Hold”
Restoration Hardware Upgraded by ValuEngine to “Hold”


© 2006-2019 Ticker Report